Opportunistic salpingectomy (OS) during any suitable abdominal surgery is effective for reducing the incidence of ovari ...

A study published in Scientific Reports found that cannabidiol (CBD) disrupts lipid metabolism and induces apoptosis in ...

BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Cancer is affecting increasing numbers of young women with the hormone oestrogen thought to play to a central role ...

Rivkin Center’s partnership with the 30-year-old OCRA will see the Seattle-area center retire as a separate entity when the April date hits, notes its web site. Linking up with ...

For a person who loved to hike; do aerobic exercises with Billy Blanks, Gilead, Denise Austin and Jane Fonda every day (I ...

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), reducing the price target ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...

1Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...